Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System

Title:Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System

Volume: 21 Issue: 23

Author(s): Gary Hulse, Erin Kelty, Sean Hood, Amanda Norman, Maria Rita Basso and Albert Stuart Reece

Affiliation:

Keywords: Amyotrophic lateral sclerosis, benzodiazepine, central nervous system, flumazenil, GABA, idiopathic hypersomnia, Parkinson’s disease.

Abstract: This review paper discusses the central role of gamma-aminobutyric acid (GABA) in diverse physiological systems and functions and the therapeutic potential of the benzodiazepine antagonist flumazenil (Ro 15- 1788) for a wide range of disorders of the central nervous system (CNS). Our group and others have studied the potential of flumazenil as a treatment for benzodiazepine dependence. A small but growing body of research has indicated that flumazenil may also have clinical application in CNS disorders such as Parkinson’s disease, idiopathic hypersomnia and amyotrophic lateral sclerosis. Despite this body of research the therapeutic potential of flumazenil remains poorly understood and largely unrealized.

The purpose of this paper is not to provide an exhaustive review of all possible therapeutic applications for flumazenil but rather to stimulate research interest, and discussion of the exciting therapeutic potential of this drug for a range of chronic debilitating conditions.

Cite this article as:

Hulse Gary, Kelty Erin, Hood Sean, Norman Amanda, Basso Rita Maria and Reece Stuart Albert, Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System, Current Pharmaceutical Design 2015; 21(23) . https://dx.doi.org/10.2174/1381612821666150619092720